London
· Delayed Price · Currency is GBP · Price in USD Esperion Therapeutics Statistics
Total Valuation
Esperion Therapeutics has a market cap or net worth of GBP 351.96 million. The enterprise value is 452.84 million.
| Market Cap | 351.96M |
| Enterprise Value | 452.84M |
Important Dates
The next estimated earnings date is Tuesday, February 25, 2025.
| Earnings Date | Feb 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +78.21% |
| Shares Change (QoQ) | +3.25% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 195.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 32.29, with an EV/FCF ratio of -23.28.
| EV / Earnings | -6.99 |
| EV / Sales | 1.89 |
| EV / EBITDA | 32.29 |
| EV / EBIT | 33.89 |
| EV / FCF | -23.28 |
Financial Position
The company has a current ratio of 1.85
| Current Ratio | 1.85 |
| Quick Ratio | 1.28 |
| Debt / Equity | n/a |
| Debt / EBITDA | 15.57 |
| Debt / FCF | -10.31 |
| Interest Coverage | 0.28 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 3.84% |
| Return on Capital (ROIC) | 101.42% |
| Revenue Per Employee | 918,483 |
| Profits Per Employee | -269,749 |
| Employee Count | 240 |
| Asset Turnover | 1.10 |
| Inventory Turnover | 1.63 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.14% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +8.14% |
| 50-Day Moving Average | 2.46 |
| 200-Day Moving Average | 2.23 |
| Relative Strength Index (RSI) | 46.01 |
| Average Volume (20 Days) | 17,629 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.26 |
Income Statement
In the last 12 months, Esperion Therapeutics had revenue of GBP 220.44 million and -64.74 million in losses. Loss per share was -0.39.
| Revenue | 220.44M |
| Gross Profit | 140.29M |
| Operating Income | 12.28M |
| Pretax Income | -64.74M |
| Net Income | -64.74M |
| EBITDA | 12.31M |
| EBIT | 12.28M |
| Loss Per Share | -0.39 |
Balance Sheet
The company has 107.97 million in cash and 200.67 million in debt, giving a net cash position of -92.70 million.
| Cash & Cash Equivalents | 107.97M |
| Total Debt | 200.67M |
| Net Cash | -92.70M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -276.21M |
| Book Value Per Share | -1.41 |
| Working Capital | 105.71M |
Cash Flow
In the last 12 months, operating cash flow was -19.22 million and capital expenditures -236,514, giving a free cash flow of -19.45 million.
| Operating Cash Flow | -19.22M |
| Capital Expenditures | -236,514 |
| Free Cash Flow | -19.45M |
| FCF Per Share | n/a |
Margins
Gross margin is 63.64%, with operating and profit margins of 5.57% and -29.37%.
| Gross Margin | 63.64% |
| Operating Margin | 5.57% |
| Pretax Margin | -29.37% |
| Profit Margin | -29.37% |
| EBITDA Margin | 5.58% |
| EBIT Margin | 5.57% |
| FCF Margin | n/a |
Dividends & Yields
Esperion Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -78.21% |
| Shareholder Yield | -78.21% |
| Earnings Yield | -18.39% |
| FCF Yield | -5.53% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Esperion Therapeutics has an Altman Z-Score of -5.09. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.09 |
| Piotroski F-Score | n/a |